Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GLS | O94925 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070126 | 1.00 | MEN1 (0.54) | MEN1ALDH1A1MAPTKMT2AGLS | |
| SCHEMBL20268177 | 1.00 | MEN1 (0.54) | MEN1ALDH1A1MAPTKMT2AGLS | |
| SCHEMBL633472 | 0.91 | NR1H2 (0.49) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL633471 | 0.91 | NR1H2 (0.49) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL7926868 | 0.91 | NR1H2 (0.49) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL4975994 | 0.89 | MEN1 (0.56) | MEN1ALDH1A1MAPTKMT2AGLS | |
| SCHEMBL7256012 | 0.88 | MEN1 (0.52) | MEN1ALDH1A1MAPTKMT2AGLS | |
| SCHEMBL12125486 | 0.86 | MEN1 (0.56) | MEN1ALDH1A1MAPTKMT2AGLS | |
| SCHEMBL344915 | 0.86 | NR1H2 (0.59) | MEN1ALDH1A1MAPTKMT2AGLS | |
| SCHEMBL344916 | 0.86 | NR1H2 (0.59) | MEN1ALDH1A1MAPTKMT2AGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024259246-A1 | 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Transneural Therapeutics, Inc. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240140933-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-05-02 | — | — | US | disclosed |
| EP-4341252-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | F. Hoffmann-La Roche AG (CH) | 2024-03-27 | — | — | EP | disclosed |
| CN-117321042-A | Oxodihydro indole compounds for the treatment of inflammatory diseases or cancers | 豪夫迈·罗氏有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2022243346-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-11-24 | — | — | WO | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140933-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | IL1B, IL1A, IL1R1 | MEN1 281/4885ALDH1A1 302/4885MAPT 3322/4885 |
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | MEN1 815/4885ALDH1A1 4437/4885MAPT 3364/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 815/4885ALDH1A1 4437/4885MAPT 3364/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | MEN1 2520/4885ALDH1A1 4528/4885MAPT 3227/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 815/4885ALDH1A1 4437/4885MAPT 3364/4885 |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | MLLT1, BMI1, MEN1 | MEN1 3/4885ALDH1A1 2922/4885MAPT 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.